8-K: LifeVantage Q1 FY26 Revenue Up 0.7%, LoveBiome Integration Exceeds Expectations

LifeVantage reported a 0.7% revenue increase to $47.6 million for Q1 FY2026, with net income per diluted share rising to $0.17, as its LoveBiome acquisition integration progresses positively.

Summary

• Revenue for the first quarter of fiscal 2026 increased by 0.7% to $47.6 million compared to the prior year period.
• Net income per diluted share rose to $0.17, up from $0.14 a year ago.
• Adjusted earnings per diluted share increased to $0.18, compared to $0.15 in the prior year.
• Adjusted EBITDA decreased to $3.9 million from $4.4 million in the comparable period.
• The company completed its strategic acquisition of LoveBiome, positioning itself in the natural GLP-1 activation and microbiome health markets.
• Management noted that the integration of LoveBiome's consultant community and P84 product is exceeding expectations.
• Cash and cash equivalents stood at $13.1 million as of September 30, 2025, a decrease from $20.2 million at June 30, 2025.
• The company reiterated its full fiscal year 2026 guidance for revenue ($225 million to $240 million), adjusted EBITDA ($23 million to $26 million), and adjusted EPS ($1.00 to $1.15).
• A cash dividend of $0.045 per common share was declared, payable on December 15, 2025, to stockholders of record on December 1, 2025.

Sentiment

Score: 6

Explanation: While some financial metrics like Adjusted EBITDA and cash from operations showed declines, the company achieved modest revenue growth, increased net income and EPS, and successfully integrated a strategic acquisition (LoveBiome) which management reports is exceeding expectations. The reiteration of full-year guidance, despite a softer Q1 relative to a proportional annual run rate, suggests confidence in future performance driven by seasonality and acquisition benefits. The decline in active customers is a concern, but the increase in active consultants is a positive.

Positives

• Revenue increased by 0.7% to $47.6 million for the first quarter of fiscal 2026.
• Net income per diluted share grew to $0.17 from $0.14 in the prior year period.
• Adjusted earnings per diluted share increased to $0.18 from $0.15 a year ago.
• Successfully completed the strategic acquisition of LoveBiome, expanding market presence in natural GLP-1 activation and microbiome health.
• Integration of LoveBiome's consultant community and P84 product is exceeding expectations.
• Reiterated full fiscal year 2026 guidance, indicating management confidence in future performance.
• No debt outstanding as of September 30, 2025.
• Declared a cash dividend of $0.045 per common share.
• Active Independent Consultants increased by 2.1% to 48,000.

Negatives

• Adjusted EBITDA decreased to $3.9 million from $4.4 million in the comparable prior year period.
• Gross profit as a percentage of revenue decreased to 79.5% from 79.9%, primarily due to increases in shipping and warehouse related expenses.
• Commissions and incentives expense as a percentage of revenue increased to 43.5% from 43.0%.
• Operating income decreased to $2.3 million from $2.6 million.
• Cash used from operations increased to $2.3 million during the first three months of fiscal 2026, compared to $0.6 million in the same period in fiscal 2025.
• Cash and cash equivalents decreased significantly to $13.1 million at September 30, 2025, from $20.2 million at June 30, 2025.
• Active Customers decreased by 3.9% to 73,000.
• Total Active Accounts decreased by 1.6% to 121,000.
• Revenue in the Asia/Pacific & Europe region decreased by 1.4% on a constant currency basis.

Risks

• Forward-looking statements are not guarantees of performance, and actual results could differ materially from those contained in such statements due to known and unknown risks and uncertainties.
• Potential for further deterioration to the global economic and operating environments.
• Risks discussed in greater detail in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption "Risk Factors."

Future Outlook

The company reiterated its fiscal year 2026 guidance, expecting revenue between $225 million and $240 million, adjusted EBITDA of $23 million to $26 million, and adjusted earnings per share in the range of $1.00 to $1.15. Management anticipates revenue in the second half of the fiscal year will be higher than the first half due to seasonality of its MindBody product line and the ongoing impact of the LoveBiome acquisition. The company expects a full year tax rate of approximately 24% to 26%.

Management Comments

• "The first quarter marked a pivotal milestone for LifeVantage as we focused on closing our strategic acquisition of LoveBiome, positioning us as a leader at the intersection of two rapidly expanding wellness markets: natural GLP-1 activation and microbiome health."
• "We're seeing several encouraging trends that should drive accelerating growth as we scale our combined operations and realize the full benefits of our strategic investments."
• "The integration of LoveBiome's passionate consultant community along with their flagship P84 product is already exceeding expectations and momentum is building across our business."
• "With a comprehensive wellness ecosystem that addresses multiple aspects of human health through scientifically validated activation technologies, we are uniquely positioned to serve the evolving needs of consumers worldwide."

Industry Context

LifeVantage is strategically positioning itself at the forefront of two rapidly expanding wellness markets: natural GLP-1 activation and microbiome health, through its acquisition of LoveBiome. This move aligns with increasing consumer interest in holistic health solutions and personalized nutrition, leveraging scientifically validated activation technologies to address evolving health needs.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and adjusted EPS, reiterated guidance, and declared cash dividend. Potential for future growth from strategic acquisition.
• Employees/Consultants: Positive impact from the integration of LoveBiome's consultant community, potentially expanding the network and business opportunities.
• Customers: Benefit from an expanded wellness ecosystem addressing multiple aspects of human health, including natural GLP-1 activation and microbiome health products.

Next Steps

• Payment of a cash dividend of $0.045 per common share on December 15, 2025.
• Scaling combined operations and realizing the full benefits of strategic investments, particularly from the LoveBiome acquisition.
• Continued focus on driving accelerating growth, with anticipated higher revenue in the second half of fiscal year 2026 due to seasonality and acquisition impact.

Key Dates

Recommendation

The Q1 results present a mixed picture with modest revenue growth and improved EPS, but a decline in Adjusted EBITDA and cash. The strategic acquisition of LoveBiome is a positive long-term move, and management's reiteration of full-year guidance, anticipating a stronger second half, suggests the company is on track. However, the decline in active customers and cash balance warrants caution. A "hold" recommendation reflects the balance between strategic progress and some operational headwinds, advising investors to await further evidence of sustained growth and improved cash flow as the LoveBiome integration matures and seasonality plays out.

Keywords

LifeVantage, LFVN, financial results, Q1 2026, earnings, revenue, net income, adjusted EBITDA, LoveBiome, acquisition, nutrigenomics, GLP-1 activation, microbiome health, dividend, share repurchase, health and wellness